What is the optimal measure of disease activity in PsA? Do MDA components all reflect the inflammatory process? Are they all needed or are there issues of overlap? Does MDA correlate with inflammation (biomarker and imaging)? What are the longterm effects of achieving MDA on structural progression? Does MDA adequately capture the patient perspective on treatment targets? What is the optimal treatment strategy for obtaining and maintaining MDA? Are there any additional biomarkers for achieving MDA? Does achieving MDA correlate with improved health-related quality of life? Is MDA an appropriate measure of disease in patients with axial PsA?
|